Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
62.33 K
Value Traded
241.05 K
Short % Float
0.7%
Days to Cover
2.9
-2.56%Week
-1.18%1 Month
-25.31%3 Month
-12.34%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
155.37 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
174.59 M
Total Shares
37.53 M
Float Shares
37.28 M
Insiders
0.53%
Institutions
39.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
FOCL Catalyst Timeline
Dated clinical, regulatory and corporate events for EDAP TMS S.A. American Depositary Shares
Past FDA Catalysts and PDUFA Decisions
How FOCL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 95%
Micro Cap(rank 624 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every FOCL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Horn David R.Director | Buy | 10,000 10,000 held | $4.75 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FOCL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in FOCL for Q2 2026. | ||||
FOCL Institutional Ownership Trends
FOCL Short Interest
Shares sold short, counted twice a month.
0.7%
Short % of Float
of tradable shares sold short
259.3K
Shares Sold Short
+5.6% vs prior count
2.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
89.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FOCL ranks across every disease it competes in
Competitive Position is a premium feature
See how FOCL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFOCL News
-FOCL
Jun 1, 20262026 Investor Day Nasdaq (FOCL) June 1, 2026 1
FocalTherics is gearing up for its 2026 Investor Day, highlighting its strategic transformation into a leader in robotic focal therapy. The company aims to focus on High Intensity Focused Ultrasound (HIFU) technology, especially in treating prostate cancer, while planning to discontinue its Extracorporeal Shock Wave Lithotripsy (ESWL) operations. Management projects strong revenue growth as they expand their market presence and emphasize innovative approaches in therapeutics. However, they acknowledge various risks associated with market acceptance, competition, and the transition away from non-core segments.
Read more →-FOCL
Mar 18, 2026The Global Leader in Therapeutic Ultrasound 1
Focal One is positioned as a global leader in therapeutic ultrasound, particularly in treating prostate cancer. The technology utilizes high-intensity focused ultrasound (HIFU) for optimal cancer control while preserving quality of life. With approximately 1.5 million new prostate cancer cases each year, the technology meets an urgent need in a large and underserved patient population. Positive clinical outcomes demonstrate the efficacy of HIFU compared to traditional surgical options, suggesting a paradigm shift in prostate cancer management.
Read more →-FOCL
Jan 12, 2026EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance
EDAP TMS SA announced record revenues for the fourth quarter and full year 2025, primarily from its HIFU business. The company reported a 69% increase in Focal One system placements and a 28% growth in procedures in the U.S., highlighting strong global demand. With preliminary revenue guidance for 2026 indicating continued growth, EDAP's CEO emphasized the increasing clinical validation supporting the adoption of their prostate cancer treatments. The company expects significant revenue contributions from its core and non-core businesses in the upcoming year.
Read more →-FOCL
Sep 9, 2025SECURITIES AND EXCHANGE COMMISSION
The report highlights the strong market potential of Focal One's Robotic HIFU therapy for prostate cancer, indicating its ability to address significant unmet clinical needs. With proven clinical evidence and a growing worldwide install base, the technology is positioned to transform prostate cancer treatment paradigms. The report emphasizes increasing patient and physician demand, alongside strong reimbursement support from hospitals. Overall, Focal One's focus on advanced imaging and robotic techniques represents a promising future in urological therapies.
Read more →About EDAP TMS S.A. American Depositary Shares
HeadquartersPARC D'ACTIVITES LA POUDRETTE LAMARTINE, 69120 VAULX EN VELIN, I0, 69120
BIOPHARMAWATCH ELITE PLUS
Trade the next FOCL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime